Abstract
Background: Schizophrenia is a highly heritable disorder characterized by increased cortical thinning throughout the life span. Studies have reported a shared genetic basis between schizophrenia and cortical thickness. However, no genes whose expression is related to abnormal cortical thinning in schizophrenia have been identified. Methods: We conducted linear mixed models to estimate the rates of accelerated cortical thinning across 68 regions from the Desikan-Killiany atlas in individuals with schizophrenia compared with healthy control participants from a large longitudinal sample (ncases = 169 and ncontrols = 298, ages 16–70 years). We studied the correlation between gene expression data from the Allen Human Brain Atlas and accelerated thinning estimates across cortical regions. Finally, we explored the functional and genetic underpinnings of the genes that contribute most to accelerated thinning. Results: We found a global pattern of accelerated cortical thinning in individuals with schizophrenia compared with healthy control participants. Genes underexpressed in cortical regions that exhibit this accelerated thinning were downregulated in several psychiatric disorders and were enriched for both common and rare disrupting variation for schizophrenia and neurodevelopmental disorders. In contrast, none of these enrichments were observed for baseline cross-sectional cortical thickness differences. Conclusions: Our findings suggest that accelerated cortical thinning, rather than cortical thickness alone, serves as an informative phenotype for neurodevelopmental disruptions in schizophrenia. We highlight the genetic and transcriptomic correlates of this accelerated cortical thinning, emphasizing the need for future longitudinal studies to elucidate the role of genetic variation and the temporal-spatial dynamics of gene expression in brain development and aging in schizophrenia.
| Original language | English |
|---|---|
| Pages (from-to) | 376-389 |
| Number of pages | 14 |
| Journal | Biological psychiatry |
| Volume | 96 |
| Issue number | 5 |
| Early online date | 21 Mar 2024 |
| DOIs | |
| Publication status | Published - 1 Sept 2024 |
Bibliographical note
Publisher Copyright:© 2024 Society of Biological Psychiatry
Funding
This work was supported by Spanish Ministry of Science , Innovation and Universities Instituto de Salud Carlos III (Grant Nos. SAM16PE07CP1 , PI16/02012 , PI17/00997 , PI19/01024 , and PI20/00721 ), cofinanced by European Regional Development Funds from the European Commission, \u201CA way of making Europe,\u201D CIBERSAM (Centro de Investigaci\u00F3n Biom\u00E9dica en Red de Salud Menta); Madrid Regional Government (Grant No. B2017/BMD-3740 AGES-CM-2 ), European Union Structural Funds; the European Union Seventh Framework Program (Grant Nos. FP7-4-HEALTH-2009-2.2.1-2-241909 [Project EU-GEI], FP7- HEALTH-2013-2.2.1-2-603196 [Project PSYSCAN], and FP7-HEALTH-2013-2.2.1-2-602478 [Project METSY]); and the European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (Grant No. 115916, Project PRISM, and Grant No. 777394, Project AIMS-2-TRIALS), Fundaci\u00F3n Familia Alonso, Fundaci\u00F3n Alicia Koplowitz, and Fundaci\u00F3n Mutua Madrile\u00F1a. CMD-C holds a Juan Rod\u00E9s Grant from Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (Grant No. JR19/00024). JG-P held a Sara Borrell grant during the development of the research from Instituto de Salud Carlos III (Grant No. CD20/00118). CA has been a consultant to or has received honoraria or grants from Acadia, Angelini, Gedeon Richter, Janssen Cilag, Lundbeck, Otsuka, Roche, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion, and Takeda. CMD-C has received honoraria from AbbVie, Sanofi, and Exeltis. BC-F has received honoraria (advisory board and educational lectures) and travel expenses from Takeda, Menarini, Angelini, Teva, Otsuka, Lundbeck, and Johnson & Johnson. He has also received unrestricted research grants from Lundbeck. XG received a grant from Fundaci\u00F3n Instituto Roche. All other authors report no biomedical financial interests or potential conflicts of interest.
| Funders | Funder number |
|---|---|
| Fundación Familia Alonso | |
| Instituto de Salud Carlos III | |
| Fundación Alicia Koplowitz | |
| European Commission | |
| Fundación Instituto Roche | |
| Centro de Investigación Biomédica en Red de Salud Mental | |
| Fundación Mutua Madrileña | |
| FP7 Health | |
| European Regional Development Fund | |
| Seventh Framework Programme | FP7-4-HEALTH-2009-2.2.1-2-241909, FP7- HEALTH-2013-2.2.1-2-603196 |
| Innovative Medicines Initiative | 115916, AIMS-2-TRIALS, 777394 |
| Ministerio de Ciencia e Innovación | CD20/00118, JR19/00024 |
| Ministerio de Ciencia, Innovación y Universidades | PI17/00997, PI19/01024, PI20/00721, SAM16PE07CP1, PI16/02012 |
| Madrid Regional Government | B2017/BMD-3740 AGES-CM-2 |
Keywords
- Brain imaging
- Cortical thinning
- Genetics
- Schizophrenia
- Transcriptomics